JC03 Rec'd PCT/PTO 1 5 NOV 2005

(C) - 1	ibute for	Form III S DEDARTMENT OF COMM	ERSE PATENT AND TRADEMARK OFFICE	TATTOTHEVIC DOOKET AND MEET						
PTO	1390		- · - · - · · · · · · · · · · · · · · ·	ATTORNEY'S DOCKET NUMBER						
		TRANSMITTAL LETTER T		032487-010 U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
		DESIGNATED/ELECTED (CONCERNING A FILING U		1						
INT	FRN	IATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	10/520,521 /						
	_,,,,	PCT/FR03/02151	07/09/2003	07/09/2002						
ππ	ΕO	FINVENTION	1 0770072000	0770072002						
บร	E C	OF ASPARTIC PROTEASES II	N COSEMETICS AND THERAPEUT	ics						
ADI	<u> </u>	ANT(S) FOR DO/FO/LIS		· · · · · · · · · · · · · · · · · · ·						
	APPLICANT(S) FOR DO/EO/US									
סט	min	ique BERNARD and Bruno Mi	EHUL							
Anı	nlicar	nt herewith submits to the United State	es Designated/Elected Office (DO/EO/US) the	following items and other information:						
1.			concerning a filing under 35 U.S.C. 371.	tonowing terms and outer unormation.						
_	=		- ·	25.1.2.0.074						
2.	×		T submission of items concerning a filing unde							
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (22) indicated below.								
4.		The US has been elected by the exp	iration of 19 months from the priority date (Arti	icle 31).						
5.		A copy of the International Application	n as filed (35 U.S.C. 371(c)(2))							
		a. is attached hereto (required	only if not communicated by the International I	Bureau).						
		b. has been communicated by	the International Bureau.							
		c. is not required, as the application	ation was filed in the United States Receiving	Office (RO/US).						
6.		An English language translation of th	e International Application as filed (35 U.S.C.	371(c)(2))						
		a. is attached hereto.								
		b. has been previously submitte	ed under 35 U.S.C. 154(d)(4).							
7										
• •		 Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). 								
		b. have been communicated by the International Bureau.								
		c. have not been made; however, the time limit for making such amendments has NOT expired.								
		d. have not been made and will		The Text of Sapiros.						
8.	П			10 (35 II C C 371(h)(3))						
9.	×	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).								
	_	(7)								
10.		An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
	Iten	ns 11 to 21 below concern documer	nt(s) or information included:							
11.		An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.							
12.		An assignment document for recording	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13.		A FIRST preliminary amendment.								
14.		A SECOND or SUBSEQUENT prelim	ninary amendment.							
15.		A substitute specification.								
16.		A change of power of attorney and/or	r address letter.							
17.	X	A computer-readable form of the seq	uence listing in accordance with PCT Rule 13	ter.2 and 37 C.F.R. 1.821 - 1.825.						
18.		A second copy of the published interest	national application under 35 U.S.C. 154(d)(4)).						
19.		A second copy of the English langua	ge translation of the international application u	under 35 U.S.C. 154(d)(4).						
20.	Other items or information: _Submission of Documents (Sequence Listing) (including paper copy of sequence listing (18 page									
	sing Requirements Under 35 U.S.C. 371 in the									
		United States Designated/Elected Of	ffice (DO/EO/US); Return Receipt Postcard	· · · · · · · · · · · · · · · · · · ·						

J.S. AP	PLICATION NO. (If known, see 37 CFR 1.5)	INTERNAT	IONAL APPLICATION N	IO. ATTOR		NEY'S DOCKET NUMBER		
	10/520,521		PCT/FR03/02151			032487-01	0	
1. 🔀	Applicant(s) requests that the publish information: L'OREAL 14. rue Royale 75008 Paris	ned applicati	on include the following	assignmen	t 	CALCULATIONS	PTO USE ONLY	
	FRANCE							
								
	The following fees are submitted:							
	ic Filing Fee (1631)							
	Surcharge of \$130.00 (1617) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).					\$ 0.00 \$		
	CLAIMS NUMBER		NUMBER EXTRA	RA [*]				
	Il Claims	-20 =	0	× \$50.00		\$ 0.00		
	pendent Claims	3 =	0	× \$200.0		\$ 0.00		
	TIPLE DEPENDENT CLAIM(S) (if ap	plicable)		+ \$360.0	<u> </u>			
	mination Fee		<u> </u>	+ \$200.0 + \$500.0				
	rch Fee			+ \$500.0	0 (1632)			
Арр	Size Fee (add \$250.00 for each add	150 sheets e			ATIONIC -	6.0.00		
	A distribution and the state of	C 27 CEE	TOTAL OF ABOVE		4HONS =	\$ 0.00		
	Applicant claims small entity status. are reduced by 1/2.	See 3/ CFF	(1.27. The lees indicate	above	+	\$ 0.00		
				SUE	STOTAL =	\$ 0.00		
Pro- mor	cessing fee of \$130.00 (1618) for fun ths from the earliest claimed priority of	nishing the E date (37 CFF	inglish translation later to R 1.492(f)).	han 20	30	\$ 0.00		
		<u>.</u>		AL NATION	AL FEE =	\$ 0.00	***	
Fee acc	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (8021) per property +							
	TOTAL FEES ENCLOSED							
	-					Amount to be refunded :		
a.	A check in the amount of		to cover the above fees	s is enclose	a.	charged :		
b.	Please charge my Deposit Account No. <u>02-4800</u> in the amount of to cover the above fees. A duplicate copy of this sheet is enclosed.							
C.	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No02-4800 A duplicate copy of this sheet is enclosed.							
d.	☐ Charge to cre	edit card. Fo	orm PTO-2038 is attache	ed.				
NO or (NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.							
J. (-,,		, ,		Λ	PA		
SE	ND ALL CORRESPONDENCE TO:		·)	lum	n Dotal	ler	
Inc	chanan Ingersoll LLP luding attorneys from Burns, [230 El Camino Real	rneys from Burns, Doane, Swecker & Mathis			TURE	1 / / / /		
Su	ite 300					Susan B. Fulle	γ.	
	n Diego, CA 92130-2090			NAME				
(85	58) 509-7300				51,979	Novem	ber 15, 2005	
				DECIS	TRATION		DATE	



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FIRST NAMED APPLICANT ATTY. DOCKET NO. U.S. APPLICATION NUMBER NO. 10/520,521 Dominique Bernard 032487-010

INTERNATIONAL APPLICATION NO.

PCT/FR03/02151

I.A. FILING DATE

PRIORITY DATE

07/09/2003

07/09/2002

Burns Doane Swecker & Mathis P O Box 1404 Alexandria, VA 22313-1404

> **CONFIRMATION NO. 9358** 371 FORMALITIES LETTER

OC000000017045935

Date Mailed: 09/20/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

Copy of the International Application filed on 01/07/2005

Copy of the International Search Report filed on 01/07/2005

Preliminary Amendments filed on 01/07/2005

- Information Disclosure Statements filed on 01/07/2005
- Biochemical Sequence Diskette filed on 01/07/2005
- Copy of references cited in ISR filed on 01/07/2005
- U.S. Basic National Fees filed on 01/07/2005
- Priority Documents filed on 01/07/2005

IAN INGERSOLL PC SFP 22 2005 DOCKETED

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825

(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

CHRISTINE S WASHINGTON

Telephone: (703) 308-9140 EXT 228

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/520,521	PCT/FR03/02151	032487-010

FORM PCT/DO/EO/905 (371 Formalities Notice)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Dominique BERNARD and Bruno MEHUL

EV793689071US

Application No.: 10/520,521

Filed: January 7, 2005

For:

USE OF ASPARTIC PROTEASES IN COSMETICS AND

THERAPEUT!CS

DECLARATION OF MAILING BY "EXPRESS MAIL"

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Kim A. Cabello declares as follows:

1. I am an employee of Buchanan Ingersoll, LLP. My business address is:

12230 El Camino Real Suite 300 San Diego, CA 92130 (858) 509-7300

- 2. On November 15, 2005, I deposited in the mail "Express Mail Post Office to Addressee" service of the United States Postal Service, the contents of the envelope for which "Express Mail" receipt No. EV 793 689 071 US was issued addressed to MAIL STOP PCT. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
 - 3. Attached hereto is a true copy of the Express Mail receipt No. EV 793 689 071 US.
- 4. I hereby declare that all statements made herein are of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the above-identified application or any patents issued thereon.

Date: November 15, 2005